Search
Atea Pharmaceuticals Inc
AVIRAdd to Watchlist
4.980USD
+0.200+4.18%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
398.53MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+4.18%
5 Days
+10.91%
1 Month
+12.67%
6 Months
+43.10%
Year to Date
+39.50%
1 Year
+33.16%
Key Figures
4.780Open
5.035High
415.18KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.52%Turnover Ratio
4.780Prev. Close
4.780Low
1.54MTurnover
LossP/E Static
1.71P/B
0.00%Div Yield TTM
-47.95%ROA
6.45052wk High
1.17Volume Ratio
-168.38MNet Profit
80.03MShares
-2.1143EPS TTM
0.34Beta
-52.58%ROE
2.78052wk Low
5.33%Amplitude
--Gross Margin
398.53MMarket Cap
2.55Reward/Risk
3.19%Risk Rate
TradingKey Stock Score of Atea Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Atea Pharmaceuticals Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 89 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Atea Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Atea Pharmaceuticals Inc Highlights
StrengthsRisks
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -2.36, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 56.77M shares, decreasing 3.79% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 325.27K shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
8.000
Target Price
+67.36%
Upside Space
Atea Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Atea Pharmaceuticals Inc Info
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
Ticker SymbolAVIR
CompanyAtea Pharmaceuticals Inc
CEOSommadossi (Jean-Pierre)
Websitehttps://ateapharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Atea Pharmaceuticals Inc (AVIR)?
The current price of Atea Pharmaceuticals Inc (AVIR) is 4.98.
What is the symbol of Atea Pharmaceuticals Inc?
The ticker symbol of Atea Pharmaceuticals Inc is AVIR.
What is the 52-week high of Atea Pharmaceuticals Inc?
The 52-week high of Atea Pharmaceuticals Inc is 6.45.
What is the 52-week low of Atea Pharmaceuticals Inc?
The 52-week low of Atea Pharmaceuticals Inc is 2.78.
What is the market capitalization of Atea Pharmaceuticals Inc?
The market capitalization of Atea Pharmaceuticals Inc is 398.53M.
Is Atea Pharmaceuticals Inc (AVIR) currently rated as Buy, Hold, or Sell?
According to analysts, Atea Pharmaceuticals Inc (AVIR) has an overall rating of Buy, with a price target of 8.00.
What is the Earnings Per Share (EPS TTM) of Atea Pharmaceuticals Inc (AVIR)?
The Earnings Per Share (EPS TTM) of Atea Pharmaceuticals Inc (AVIR) is -1.94.